Jack Bendheim Sells 13,158 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 13,158 shares of the stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $41.98, for a total value of $552,372.84. Following the transaction, the chief executive officer owned 18 shares of the company’s stock, valued at approximately $755.64. The trade was a 99.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.68, for a total value of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.02, for a total value of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.53, for a total transaction of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total transaction of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.16, for a total transaction of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total transaction of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.19, for a total transaction of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.06, for a total value of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.77, for a total value of $143,510.40.

Phibro Animal Health Stock Performance

PAHC opened at $39.01 on Friday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.35 and a current ratio of 3.09. The business’s 50-day simple moving average is $40.16 and its 200 day simple moving average is $37.47. The firm has a market capitalization of $1.58 billion, a PE ratio of 23.50, a PEG ratio of 1.18 and a beta of 0.79. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $46.42.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.15. The firm had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. As a group, sell-side analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th were given a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend was Wednesday, November 26th. Phibro Animal Health’s dividend payout ratio is 28.92%.

Hedge Funds Weigh In On Phibro Animal Health

Several institutional investors and hedge funds have recently made changes to their positions in the company. Capricorn Fund Managers Ltd bought a new stake in Phibro Animal Health in the 3rd quarter valued at $10,233,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Phibro Animal Health during the third quarter worth $8,931,000. Voya Investment Management LLC boosted its position in shares of Phibro Animal Health by 44.3% in the first quarter. Voya Investment Management LLC now owns 31,894 shares of the company’s stock valued at $681,000 after acquiring an additional 9,796 shares during the period. Bailard Inc. acquired a new position in shares of Phibro Animal Health in the second quarter valued at about $259,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Phibro Animal Health in the second quarter valued at about $813,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PAHC. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Finally, JPMorgan Chase & Co. raised their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Phibro Animal Health currently has a consensus rating of “Hold” and an average target price of $31.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.